Jonathan Gutman is an Oncology physician affiliated with University of Colorado Denver. OpenAlex indexes 220 publications with 11,365 citations (h-index 39); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12605 E 16th Ave
Aurora, CO 800452545
Telephone
720-848-0000Registry record last updated 19 Nov 2018.
Clinical trials
- Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Sponsor: University of Colorado, Denver
- Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Sponsor: University of Colorado, Denver
- Shingrix In Recipients of Allogeneic Transplants
Sponsor: University of Colorado, Denver
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gamida Cell Inc.Program year20251 payment
- National Marrow Donor ProgramProgram year20251 payment
- Melinta Therapeutics, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.7%Kinase inhibitor19.9%Jakafi100%Part D<11 patientsSelective immunosuppressants8.6%Rezurock100%Part D<11 patients+ 1 more class in this area
Dermatology
29.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor29.3%Acyclovir100%Part D≥27 patientsAnti-infectives
13.5%Short-acting sulfonamides9.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.1%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Tyler Buckner, MD
University of Colorado Denver
Gary Larsen, MD
University of Colorado Denver
Lindsay Boyers, MD
University of Colorado Denver
Bettina Cuneo, MD
University of Colorado Denver
Carl June, MD
University of Pennsylvania
Christopher Benz, MD
Buck Institute for Research on Aging
Christina Fitzmaurice, MD
Gundersen Health System
Beth Karlan, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”